Protara Therapeutics Q2 EPS $(0.45) Beats $(0.80) Estimate
Portfolio Pulse from Benzinga Newsdesk
Protara Therapeutics (NASDAQ:TARA) reported a Q2 EPS of $(0.45), beating the analyst estimate of $(0.80) by 43.75%. This represents a 55% improvement over the $(1.00) loss per share from the same period last year.
August 06, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protara Therapeutics reported a Q2 EPS of $(0.45), significantly beating the analyst estimate of $(0.80) and showing a 55% improvement year-over-year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100